Vionelix Pharmaceuticals
Vionelix Pharmaceuticals is an early-stage Anglo-American biotech company focused on revolutionizing antiviral therapies through its proprietary RAPTOR-AI™ platform. This AI-driven drug discovery platform designs resistance-proof, direct-acting antiviral drugs that target viral protein synthesis, offering effectiveness against treatment-resistant infections and rapidly mutating pathogens. Vionelix aims to treat a range of viruses including influenza, hepatitis B, smallpox, and COVID-19, with a development and manufacturing process that is faster and more cost-efficient than traditional biologics and vaccines. Their drugs are designed for easy administration and suitability as post-exposure prophylaxis. The company holds intellectual property protection for its scientific methods and AI-assistance package, with a business model that includes outsourcing manufacturing and development to specialized contract organizations and a flexible approach to drug commercialization through direct sales, marketing, or licensing agreements.
Vionelix Pharmaceuticals
Vionelix Pharmaceuticals is an early-stage Anglo-American biotech company focused on revolutionizing antiviral therapies through its proprietary RAPTOR-AI™ platform. This AI-driven drug discovery platform designs resistance-proof, direct-acting antiviral drugs that target viral protein synthesis, offering effectiveness against treatment-resistant infections and rapidly mutating pathogens. Vionelix aims to treat a range of viruses including influenza, hepatitis B, smallpox, and COVID-19, with a development and manufacturing process that is faster and more cost-efficient than traditional biologics and vaccines. Their drugs are designed for easy administration and suitability as post-exposure prophylaxis. The company holds intellectual property protection for its scientific methods and AI-assistance package, with a business model that includes outsourcing manufacturing and development to specialized contract organizations and a flexible approach to drug commercialization through direct sales, marketing, or licensing agreements.